282 related articles for article (PubMed ID: 10519421)
1. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells.
Bandyopadhyay A; Zhu Y; Cibull ML; Bao L; Chen C; Sun L
Cancer Res; 1999 Oct; 59(19):5041-6. PubMed ID: 10519421
[TBL] [Abstract][Full Text] [Related]
2. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
[TBL] [Abstract][Full Text] [Related]
3. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells.
Ye SC; Foster JM; Li W; Liang J; Zborowska E; Venkateswarlu S; Gong J; Brattain MG; Willson JK
Cancer Res; 1999 Sep; 59(18):4725-31. PubMed ID: 10493532
[TBL] [Abstract][Full Text] [Related]
4. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
[TBL] [Abstract][Full Text] [Related]
5. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells.
Bandyopadhyay A; Zhu Y; Malik SN; Kreisberg J; Brattain MG; Sprague EA; Luo J; López-Casillas F; Sun LZ
Oncogene; 2002 May; 21(22):3541-51. PubMed ID: 12032856
[TBL] [Abstract][Full Text] [Related]
6. Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line.
Park B; Jang JS; Park K
Int J Oncol; 2000 Sep; 17(3):473-8. PubMed ID: 10938386
[TBL] [Abstract][Full Text] [Related]
7. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
8. Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells.
Sun L; Chen C
J Biol Chem; 1997 Oct; 272(40):25367-72. PubMed ID: 9312157
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.
Bandyopadhyay A; López-Casillas F; Malik SN; Montiel JL; Mendoza V; Yang J; Sun LZ
Cancer Res; 2002 Aug; 62(16):4690-5. PubMed ID: 12183427
[TBL] [Abstract][Full Text] [Related]
10. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
Ko Y; Banerji SS; Liu Y; Li W; Liang J; Soule HD; Pauley RJ; Willson JK; Zborowska E; Brattain MG
J Cell Physiol; 1998 Aug; 176(2):424-34. PubMed ID: 9648930
[TBL] [Abstract][Full Text] [Related]
11. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
Yamamoto N; Imai J; Watanabe M; Hiroi N; Sugano S; Yoshino G
Horm Metab Res; 2006 Mar; 38(3):159-66. PubMed ID: 16673206
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone.
Mourskaia AA; Dong Z; Ng S; Banville M; Zwaagstra JC; O'Connor-McCourt MD; Siegel PM
Oncogene; 2009 Feb; 28(7):1005-15. PubMed ID: 19079339
[TBL] [Abstract][Full Text] [Related]
13. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
[TBL] [Abstract][Full Text] [Related]
14. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
Okamoto M; Oyasu R
Cell Growth Differ; 1997 Aug; 8(8):921-6. PubMed ID: 9269901
[TBL] [Abstract][Full Text] [Related]
16. Autocrine TGFbeta supports growth and survival of human breast cancer MDA-MB-231 cells.
Lei X; Bandyopadhyay A; Le T; Sun L
Oncogene; 2002 Oct; 21(49):7514-23. PubMed ID: 12386814
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis.
Kominsky SL; Doucet M; Brady K; Weber KL
J Bone Miner Res; 2007 Jan; 22(1):37-44. PubMed ID: 17032147
[TBL] [Abstract][Full Text] [Related]
18. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB
Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662
[TBL] [Abstract][Full Text] [Related]
19. Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells.
Chang J; Lee C; Hahm KB; Yi Y; Choi SG; Kim SJ
Oncogene; 2000 Jan; 19(1):151-4. PubMed ID: 10644990
[TBL] [Abstract][Full Text] [Related]
20. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
Tang B; de Castro K; Barnes HE; Parks WT; Stewart L; Böttinger EP; Danielpour D; Wakefield LM
Cancer Res; 1999 Oct; 59(19):4834-42. PubMed ID: 10519393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
